Search This Blog

Wednesday, August 28, 2019

Lannett’s bullish outlook buoys generic players

Lannett Company (LCI +43.4%) is up on a healthy 11x surge in volume after reporting fiscal Q4 results after the close yesterday that included bullish fiscal 2020 guidance that investors hope signals a long-awaited turnaround for the beaten-down industry.
Selected tickers: Aclaris Therapeutics (ACRS +2.2%), Akorn (AKRX+4.3%), ANI Pharmaceuticals (ANIP +0.6%), Bausch Health Companies (BHC +0.8%), Teva Pharmaceutical Industries (TEVA +3.4%), Collegium Pharmaceutical (COLL +1.7%), Eagle Pharmaceuticals (EGRX +0.8%), Mylan N.V. (MYL +2.1%), Perrigo (PRGO +1.6%), Teligent (TLGT +0.8%)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.